Impact of malnutrition and social determinants on survival of HIV-infected adults starting antiretroviral therapy in resource-limited settings

AIDS

Volumn 26, Issue 9, 2012, Pages 1161-1166

  Argemi, Xavier ^a   Dara, Som ^b   You, Seng ^b   Mattei, Jean F ^c   Courpotin, Christian ^c   Simon, Bernard ^c   Hansmann, Yves ^a   Christmann, Daniel ^a   Lefebvre, Nicolas ^a  

^a HÔPITAL CIVIL   (France)

^b Junka Jek Hospital   (Cambodia)

^c Department of International Relations ^*  (France)

Author keywords

anaemia; HIV; malnutrition; mortality; social determinants

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BODY MASS; CAMBODIA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DESCRIPTIVE RESEARCH; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RURAL AREA; SURVIVAL;

ADULT; ANEMIA; ANTI-HIV AGENTS; CAMBODIA; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MALNUTRITION; RETROSPECTIVE STUDIES; RISK FACTORS; RURAL HEALTH; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84861529319     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328353f363     Document Type: Article

References (28)

1. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659-665.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
3. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries. Lancet 2006; 367:817-824.
4. Süttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, Mü ller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr HumRetrovirol 1995; 8:239-246.
5. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31:230-236.
6. UNAIDS. 2008 Epidemiological fact sheet on HIV and AIDS, Cambodia. http://www.unaids.org/en/CountryResponses/Countries/cambodia.asp. [Accessed 30 March 2012].
7. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007; 21:2293-2301.
8. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21:2483-2491.
9. Ferro-Luzzi A, Sette S, Franklin M, James WPT. A simplified approach of assessing adult chronic energy deficiency. Eur J Clin Nutr 1992; 46:173-186.
10. World Health Organisation (WHO). Worldwide prevalence of anaemia 1993-2005-WHO global database on anaemia. http://www.who.int/topics/anaemia/en/. [Accessed 30 March 2012].
11. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, et al., Antiretroviral Therapy Cohort Collaboration. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008; 13:959-967.
12. O'Brien ME, Kupka R, Msamanga GI, Saathoff E, Hunter DJ, Fawzi WW. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 2005; 40:219-225.
13. Koethe JR, Lukusa A, Giganti MJ, Chi BH, Nyirenda CK, Stringer JS, et al. Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010; 53:507-513.
14. Madec Y, Szumilin E, Genevier C, Ferradini L, Balkan S, Pujades M, et al. Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries. AIDS 2009; 23:853-861.
15. Schroecksnadel K, Zangerle R, Fuchs D. Multivitamin supplements and HIV disease progression. N Engl J Med 2004; 351:1353-1354.
16. Fawzi WW, Msamanga GI, Spiegelman D, Wei R, Kapiga S, Villamor E, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351:23-32.
17. Koethe JR, Chi BH, Megazzini KM, Heimburger DC, Stringer JS. Macronutrient supplementation for malnourished HIVinfected adults: a review of the evidence in resource-adequate and resource-constrained settings. Clin Infect Dis 2009; 49:787-798.
18. Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet 2002; 360:235.
19. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363:157-163.
20. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999; 13:943-950.
21. Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20:1181-1189.
22. De Beaudrap P, Etard JF, Ecochard R, Diouf A, Dieng AB, Cilote V, et al. Change over time of mortality predictors after HAART initiation in a Senegalese cohort. Eur J Epidemiol 2008; 23:227-234.
23. Lutalo T, Gray RH, Wawer M, Sewankambo N, Serwadda D, Laeyendecker O, et al. Survival of HIV-infected treatmentnaive individuals with documented dates of seroconversion in Rakai, Uganda. AIDS 2007; 21 (Suppl 6):S15-S19.
24. Zachariah R, Harries K, Moses M, Manzi M, Line A, Mwagomba B, et al. Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi. Trop Med Int Health 2009; 14:713-721.
25. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
26. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355-2360.
27. Antiretroviral Therapy Cohort Collaboration. Mortality of HIVinfected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38:1624-1633.
28. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health 2009; 14:722-731.